Krystal Biotech, Inc. (KRYS)Healthcare | Biotechnology | Pittsburgh, United States | NasdaqGS
274.21 USD
+10.15
(3.844%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 274.14 -0.07 (-0.070%) ⇩ (April 17, 2026, 5:47 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★★★☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:25 p.m. EDT
Krystal Biotech (KRYS) presents a mixed picture. The short-term price forecast shows a slight downward trend, but the strong analyst ratings and positive fundamentals suggest potential for long-term growth. The recent pullback may offer a buying opportunity for long-term investors, especially given the positive earnings growth and strong revenue growth. However, the lack of dividends and the high overall risk should be considered. Options activity indicates a cautious market, with both bullish and bearish positions, suggesting potential for volatility in the near term. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.052629 |
| AutoARIMA | 0.054622 |
| MSTL | 0.059996 |
| AutoTheta | 0.161958 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 6.84 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.654 |
| Excess Kurtosis | -0.57 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.766 |
| Revenue per Share | 13.444 |
| Market Cap | 8,071,575,552 |
| Trailing P/E | 40.15 |
| Forward P/E | 25.92 |
| Beta | 0.54 |
| Profit Margins | 52.64% |
| Website | https://www.krystalbio.com |
As of April 11, 2026, 4:25 p.m. EDT: Options activity suggests a mix of bullish and bearish sentiment. The calls show significant positioning in the 270 strike, with high open interest and volume, indicating potential for upward movement. However, puts also show notable activity, especially around the 260 strike, suggesting some bearish speculation. The IV spikes and volume spikes in certain strikes indicate heightened uncertainty or anticipated volatility. Overall, the options market is signaling a cautious approach with potential for both upward and downward moves.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.6935952 |
| Address1 | 2,100 Wharton Street |
| Address2 | Suite 701 |
| All Time High | 298.303 |
| All Time Low | 8.03 |
| Ask | 345.42 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 260,080 |
| Average Daily Volume3 Month | 287,287 |
| Average Volume | 287,287 |
| Average Volume10Days | 260,080 |
| Beta | 0.538 |
| Bid | 198.51 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 41.777 |
| City | Pittsburgh |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 274.21 |
| Current Ratio | 9.953 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 276.24 |
| Day Low | 267.31 |
| Debt To Equity | 0.766 |
| Display Name | Krystal Biotech |
| Earnings Call Timestamp End | 1,771,335,000 |
| Earnings Call Timestamp Start | 1,771,335,000 |
| Earnings Growth | 0.116 |
| Earnings Quarterly Growth | 0.13 |
| Earnings Timestamp | 1,771,335,000 |
| Earnings Timestamp End | 1,777,897,800 |
| Earnings Timestamp Start | 1,777,897,800 |
| Ebitda | 162,919,008 |
| Ebitda Margins | 0.41867 |
| Enterprise To Ebitda | 44.177 |
| Enterprise To Revenue | 18.496 |
| Enterprise Value | 7,197,306,368 |
| Eps Current Year | 7.73589 |
| Eps Forward | 10.57953 |
| Eps Trailing Twelve Months | 6.83 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 262.6432 |
| Fifty Day Average Change | 11.566803 |
| Fifty Day Average Change Percent | 0.044039987 |
| Fifty Two Week Change Percent | 69.35952 |
| Fifty Two Week High | 298.303 |
| Fifty Two Week High Change | -24.093018 |
| Fifty Two Week High Change Percent | -0.08076693 |
| Fifty Two Week Low | 122.8 |
| Fifty Two Week Low Change | 151.40999 |
| Fifty Two Week Low Change Percent | 1.2329804 |
| Fifty Two Week Range | 122.8 - 298.303 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,505,914,200,000 |
| Float Shares | 23,164,464 |
| Forward Eps | 10.57953 |
| Forward P E | 25.91892 |
| Free Cashflow | 93,933,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 295 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.94077003 |
| Gross Profits | 366,080,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11408 |
| Held Percent Institutions | 0.9867 |
| Implied Shares Outstanding | 29,435,746 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. |
| Long Name | Krystal Biotech, Inc. |
| Market | us_market |
| Market Cap | 8,071,575,552 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_534062888 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 204,831,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,071,281,553 |
| Number Of Analyst Opinions | 9 |
| Open | 268.88 |
| Operating Cashflow | 200,864,992 |
| Operating Margins | 0.41333 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 412 586 5830 |
| Post Market Change | -0.06997681 |
| Post Market Change Percent | -0.025519423 |
| Post Market Price | 274.14 |
| Post Market Time | 1,776,462,449 |
| Previous Close | 264.06 |
| Price Eps Current Year | 35.44647 |
| Price Hint | 2 |
| Price To Book | 6.563659 |
| Price To Sales Trailing12 Months | 20.74262 |
| Profit Margins | 0.52638 |
| Quick Ratio | 9.279 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.18182 |
| Region | US |
| Regular Market Change | 10.15 |
| Regular Market Change Percent | 3.84382 |
| Regular Market Day High | 276.24 |
| Regular Market Day Low | 267.31 |
| Regular Market Day Range | 267.31 - 276.24 |
| Regular Market Open | 268.88 |
| Regular Market Previous Close | 264.06 |
| Regular Market Price | 274.21 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 307,410 |
| Return On Assets | 0.08437 |
| Return On Equity | 0.18913999 |
| Revenue Growth | 0.175 |
| Revenue Per Share | 13.444 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 29,435,746 |
| Shares Percent Shares Out | 0.1066 |
| Shares Short | 3,136,891 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,947,930 |
| Short Name | Krystal Biotech, Inc. |
| Short Percent Of Float | 0.1751 |
| Short Ratio | 11.08 |
| Source Interval | 15 |
| State | PA |
| Symbol | KRYS |
| Target High Price | 371.0 |
| Target Low Price | 241.0 |
| Target Mean Price | 314.0 |
| Target Median Price | 310.0 |
| Total Cash | 827,790,976 |
| Total Cash Per Share | 28.318 |
| Total Debt | 9,339,000 |
| Total Revenue | 389,129,984 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 6.83 |
| Trailing P E | 40.147877 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 211.56717 |
| Two Hundred Day Average Change | 62.642822 |
| Two Hundred Day Average Change Percent | 0.29608953 |
| Type Disp | Equity |
| Volume | 307,410 |
| Website | https://www.krystalbio.com |
| Zip | 15,203 |